How did MD's revenue and expenses trend in Q4 2024 compared to previous quarters?


Aime
Pediatrix Medical Group (MD) experienced a general upward trend in revenue and a decrease in expenses from Q3 to Q4 2024, with some fluctuations. Here's a detailed analysis:
- Revenue Trend:
- Q4 2024: MD's total revenue was $502.36 million1.
- Q3 2024: The revenue was slightly higher at $511.16 million1.
- Q2 2024: Revenue was $504.3 million1.
- Q1 2024: The lowest revenue was recorded at $495.1 million1.
- The revenue trend shows an increase from Q1 to Q2, remained stable from Q2 to Q3, and slightly decreased from Q3 to Q4.
- Expense Trend:
- No data is available for MD's expenses in Q4 20242.
- However, from Q3 to Q4 2024, the company's net income increased from $19 million to $30 million3, indicating a potential decrease in expenses or an increase in profitability.
- Net Income and Adjusted EBITDA:
- Q4 2024: MD reported a net income of $30 million and adjusted EBITDA of $69 million3.
- Q3 2024: Net income was $19 million, and adjusted EBITDA was $60 million4.
- Q2 2024: Net loss was $153 million, with an adjusted EBITDA of $58 million5.
- Q1 2024: No data is available for net income or adjusted EBITDA.
- Institutional Activity and Analyst Ratings:
- Institutional investors showed interest with several buying and selling activities67.
- Analyst ratings included upgrades and downgrades, with price target adjustments910.
In conclusion, MD's revenue showed a seasonal fluctuation with a peak in Q3 2024, a slight dip in Q4 2024, and a general upward trend from Q1 to Q2 2024. The net income and adjusted EBITDA improved from Q3 to Q4 2024, suggesting a potential decrease in expenses or improved operational efficiency.
Source:
1.
MD Revenue in Q4 2024, Q3 2024, Q2 2024, Q1 2024
more
less
Continue this conversation 

Explore
Screener
Analysis
Learn
Wiki